Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5741858#aggregation> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B982940.
- aggregation creator B982941.
- aggregation creator B982942.
- aggregation creator B982943.
- aggregation creator B982944.
- aggregation creator B982945.
- aggregation creator B982946.
- aggregation creator B982947.
- aggregation creator B982948.
- aggregation creator B982949.
- aggregation creator B982950.
- aggregation creator person.
- aggregation date "2006".
- aggregation hasFormat 5741858.bibtex.
- aggregation hasFormat 5741858.csv.
- aggregation hasFormat 5741858.dc.
- aggregation hasFormat 5741858.didl.
- aggregation hasFormat 5741858.doc.
- aggregation hasFormat 5741858.json.
- aggregation hasFormat 5741858.mets.
- aggregation hasFormat 5741858.mods.
- aggregation hasFormat 5741858.rdf.
- aggregation hasFormat 5741858.ris.
- aggregation hasFormat 5741858.txt.
- aggregation hasFormat 5741858.xls.
- aggregation hasFormat 5741858.yaml.
- aggregation isPartOf urn:issn:0250-7005.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases".
- aggregation abstract "Background: Despite the progress made in the treatment of metastatic colorectal cancer (CRC), the results of second-line chemotherapy remain poor. Patients and Methods: The feasibility of hepatic arterial infusion (HAI) of oxaliplatin (100 mg/m(2) over 6 h) followed by l-folinic acid (L-FA) (400 mg over 2 h i.v.)-modulated continuous HAI of 5-Fluorouracil (5-FU) (60 mg/kg over 42 h; q2w) as second-line chemotherapy for metastatic CRC limited to the liver was investigated. Results: A median of 9 treatment cycles were administered (range 4-14). Treatment-limiting toxicity consisted of: abdominal pain (3 patients), elevated liver enzymes accompanied by fatigue (3), elevated bilirubin (2), neutropenia (2), thrombocytopenia (3) and hypersensitivity to oxaliplatin (1). Normalization for > 4 weeks of the carcinoembryonic antigen (CEA) level was documented in 3 patients and a decline of > 50% for > 4 weeks in 5 patients. A confirmed partial response (PR) was documented in 5, stable disease (SD) in 1 and progressive disease (PD) in 3 patients. In the latter 3 patients, lung metastases developed while a PR was observed in the liver metastases. A pathological complete response (CR) was documented in 2 patients. The median time to progression was 7.2 months (95% CI 1.3-13) and the median overall survival 18.3 months (95% CI 163-20.3). Conclusion: HAI of oxaliplatin plus C15-FU/LV is feasible and merits further evaluation.".
- aggregation authorList BK1382762.
- aggregation endPage "619".
- aggregation issue "1B".
- aggregation startPage "611".
- aggregation volume "26".
- aggregation isDescribedBy 5741858.
- aggregation similarTo LU-5741858.